Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Zachs News Article mentioning Biogen and PMN ARFXF
View:
Post by DavidKingCanada on Jun 22, 2021 11:43am

Zachs News Article mentioning Biogen and PMN ARFXF

Comment by BottomBroker on Jun 22, 2021 12:26pm
Finally, a story about Biogen that actually mentions PMN. This is big IMO. And pretty sure this isn't paid content, correct?
Comment by retiredcop on Jun 22, 2021 12:41pm
Sorry to disappoint you .. Zachs is on our payroll for a few years now.. 
Comment by DavidKingCanada on Jun 22, 2021 12:46pm
Payroll or not, any mention of PMN along side Biogen is in my opinion great news to look forward to. With most Small Cap Companies, this is the kind of publicity we need. Especially when one of them is Biogen and the other PMN.to ARFXF
Comment by retiredcop on Jun 22, 2021 12:47pm
But Thats OK... Zachs is able to make assumptions, predictions , give estimated dates ,, which are things that PMN is not permitted to do. So look at it as a indirect way of PMN being able to say things /update the public/shareholdersin a manner they normally could offically publsh or release info.  I personally put quite a bit of credibility on what Zachs is publishing, becuase the info they ...more  
Comment by DavidKingCanada on Jun 22, 2021 12:50pm
Agreed! 
Comment by BottomBroker on Jun 22, 2021 12:56pm
Okay, so somewhere between paid content written by PMN and an independent, legitimate news story. I'm choosing to believe that's progress! Ha.  
Comment by M101 on Jun 22, 2021 5:09pm
It doesn't sound like Goldstein or his apprentice so maybe someone else approves ad copy now.  
Comment by Gbathat on Jun 22, 2021 7:24pm
Great shoutout to PMN in this article!  Awesome!!!! I really like the analysis in the article too... offers a broad perspective of the aptly labeled saga. PMN mentioned next to Eli Lilly....  so you're telling me there's a chance!  :D  :D :-)
Comment by TopBroker on Jun 22, 2021 8:33pm
With the amyloid theory being regenerated you would think a joint venture would be inevitable, but with an inept board and Gene who has never done a deal in his life, this may be impossible. What a useless board of Directors.
Comment by DavidKingCanada on Jun 22, 2021 11:24pm
Indeed excellent News for PMN.to ARFXF! Imagine buying now and Biogen actually using PMN310. The SP will rise well above $1.00-$3.00. This is a Buy at the current SP and is a Long Term Investment (3-5 Years Exit). 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities